J Neurol Neurosurg Psychiatry 53:1096-1098 doi:10.1136/jnnp.53.12.1096
  • Research Article

Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.

  1. T Bottiglieri,
  2. P Godfrey,
  3. T Flynn,
  4. M W Carney,
  5. B K Toone,
  6. E H Reynolds
  1. Department of Neurology, King's College Hospital, London, United Kingdom.


      Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.

      Visit the full archive of podcasts for JNNP here >>

      Free sample
      This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
      View free sample issue >>

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

      Navigate This Article